Skip to main content
SpringerLink
Log in

Use of 201Tl SPECT Imaging to Assess the Response to Therapy in Patients with High Grade Gliomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose. To assess the potential role of 201Tl single photon emission tomography (201-Thallium SPECT) when compared to other imaging modalities in the evaluation of the response to therapy in high grade gliomas.

Materials and methods. Twenty patients with histologically proved high grade glioma have been included: 15 with glioblastoma (GBM), 3 with anaplastic astrocytoma (AA) and 2 with anaplastic oligoastrocytoma (AOA). Patients were assessed by 201Tl SPECT, computed tomography (CT) and magnetic resonance imaging (MRI) at (a) either at the moment of maximum response to first line chemotherapy, or after the completion of radiotherapy and chemotherapy if post-surgical residual disease was present, and (b) after the completion of second line chemotherapy if disease persisted, or either a relapse or disease progression was confirmed. Final response was evaluated according to the McDonald criteria, and by comparing SPECT, CT and MRI results.

Results. According to the McDonald criteria, clinical response after first line chemotherapy was 5 partial response, 7 stable disease and 8 progressive disease. Evaluation by 201Tl SPECT was in agreement with such criteria in nearly all patients (90%). MRI findings closely agreed with the clinical follow-up. CT findings clearly differed from those observed by SPECT and MRI. After second line therapy, 10 patients progressed, 3 had stable disease and 7 had partial response. 201Tl SPECT agreed with the clinical status in 89% cases, whereas MRI and, specially CT, fared significantly lower.

Conclusion. Compared to conventional neuroimaging, 201Tl SPECT added valuable information in the assessment of the response to therapy in our patient population; whenever findings were not conclusive and in the case of disagreement between CT and MRI findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fleury A, Manegoz F, Grosclaude P, Daures JP, Henry-Amar M, Raverdy N, Schaffer P, Poisson M, Delattre JY: Descriptive epidemiology of cerebral gliomas in France. Cancer 79: 1195–1202, 1997

    Google Scholar 

  2. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol 3: 255–268, 1993

    Google Scholar 

  3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597, 1993

    Google Scholar 

  4. Levin VA: Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-Oncol 1: 69–80, 1999

    Google Scholar 

  5. Yung WK, Prados M, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Z, Levin VA: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Tumor Group. J Clin Oncol 17: 2762–2771, 1999

    Google Scholar 

  6. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolamide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588–593, 2000

    Google Scholar 

  7. Kosuda S, Fujii H, Aoki S, Suzuki K, Tanaka Y, Nakamura O, Shitara N: Prediction of survival in patients with suspected recurrent cerebral tumors by quantitative Thallium-201 single photon emission computed tomography. Int J Radiat Oncol Biol Phys 30: 1201–1206, 1994

    Google Scholar 

  8. Vertosick FT, Seiker RG, Grossman SJ, Joyce JM: Correlation of thallium-201 single photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 34: 396–401, 1994

    Google Scholar 

  9. Oriuchi N, Tamura M, Shibazaki T, Ohye C, Watanabe N, Tateno M, Tomiyoshi K, Hirano T, Inoue T, Endo K: Clinical evaluation of thallium-201 SPECT in supratentorial gliomas: relationship to histologic grade, prognosis, and proliferative activities. J Nucl Med 34: 2085–2089, 1993

    Google Scholar 

  10. Yoshii Y, Satou M, Yamamoto T, Yamada Y, Hyodo A, Nose T, Ishikawa H, Hatakeyama R: The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. Eur J Nucl Med 20: 39–45, 1993

    Google Scholar 

  11. Diercks RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP: Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 21: 621–633, 1994

    Google Scholar 

  12. Ishibashi M, Taguchi A, Sugita Y, Morita S, Kawamura S, Umezaki N, Shigemori M, Hayabuchi N: Thallium-201 in brain tumors: relationship between tumor cell activity in astrocytic tumor and proliferating cell nuclear antigen. J Nucl Med 36: 2201–2206, 1995

    Google Scholar 

  13. Arbab A, Koizumi K, Toyama K, Arai T, Araki T: Uptake of thechnetioum-99m-tetrofosmin, technetium-99m-MIBI and Thallium-201 in tumor cell lines. J Nucl Med 37: 1551–1556, 1996

    Google Scholar 

  14. Taki S, Kakuda K, Kakuma K, Kobayashi K, Ohashi M, Ito S, Yokoyama M, Annen Y, Tonami N: 201Tl SPET in the differential diagnosis of brain tumours. Nucl Med Commun 20: 637–645, 1999

    Google Scholar 

  15. Tonami N. Thallium-201 SPECT in the evaluation of gliomas. J Nucl Med 34: 2085–2089, 1993

    Google Scholar 

  16. McDonald DR, Cascino Tl, Schold Jr SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277–1280, 1990

    Google Scholar 

  17. Doom GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH: Brain radiation necrosis: MR imaging. Radiology 158: 149–155, 1986

    Google Scholar 

  18. Källen K, Heiling M, Andersson AM, Brun A, Holtas S, Ryding E: Preoperative grading of glioma malignancy with Thallium-201 single-photon emission CT: comparison with conventional CT. AJNR Am J Neuradiol 17: 925–932, 1996

    Google Scholar 

  19. Bloom M, Jacobs S, Pile-Spellman J, Pozniakoff A, Mabutas MI, Fawwaz RA: Cerebral SPECT imaging: effect on clinical management. J Nucl Med 37: 1070–1073, 1993

    Google Scholar 

  20. Källen K, Burtscher IM, Holtas S, Ryding E, Rosen I: 201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malingnant astrocytomas. J Neuro-Oncol 46: 173–185, 2000

    Google Scholar 

  21. Black KL. Emerick T, Hoh CK, Hawkins RA, Mazziota J, Becker DP: Thallium-201 SPECT and positron emission tomography equal predictors of glioma grade and recurrence. Neurol Res 16: 93–96, 1994

    Google Scholar 

  22. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT: Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs. 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 163: 1459–1462, 1994

    Google Scholar 

  23. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, Morioka T, Fukui M, Masuda K: A comparative study of thallium-201 SPET, Carbon-11–methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 25: 1261–1269, 1998

    Google Scholar 

  24. Loberboym M, Mandell LR, Mosesson RE, Germano I, Lou W, DaCosta M, Linzer DG, Machac J: The role of Thallium-201 uptake and retention in intracranial tumors after radiotherapy. J Nucl Med 38: 223–226, 1997

    Google Scholar 

  25. Roesdi MF, Postma TJ, Hoekstra OS, Van Groeningen CJ, Wolbers JG, Heimans JJ: Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neuro-Oncol 40: 251–255, 1998

    Google Scholar 

  26. Staffen W, Hondl N, Trinka E, Iglseder B, Unterrainer J, Ladurner G: Clinical relevance of 201Tl-chloride SPECT in the differential diagnosis of brain tumours. Nucl Med Commun 19: 335–340, 1998

    Google Scholar 

  27. Källen K, Geijer B, Malmstrom P, Andersson AM, Holtas S, Ryding E, Rosen I: Quantitative 201Tl SPECT imaging in the follow-up of treatment for a sensitive tool for the early identification of response to chemotherapy. Nucl Med Commun 21: 259–267, 2000

    Google Scholar 

  28. Carvalho PA, Schwartz RB, Alexander E 3rd, Garada BM, Aimmerman RE, Loeffler JS, Holman BL: Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 77(4): 565–570, 1992

    Google Scholar 

  29. Zhang JJ, Park CH, Kim SM, Ayyangar KM, Haghbin M: Dual Isotope SPECT in the evaluation of recurrent brain tumor. Clin Nucl Med 17: 663–664, 1992

    Google Scholar 

  30. Moustafa HM, Omar WM, Ezzat I, Ziada GA, el-Ghonimy EG: 201Tl single photon emission tomography in the evaluation of residual and recurrent astrocytoma. Nucl Med Commun 15: 140–143, 1994

    Google Scholar 

  31. Schwartz RB, Carvalho PA, Alexander E 3rd, Loeffler JS, Folkerth R, Holman BL: Radiation necrosis vs. highgrade recurrent glioma: differentiation by using dual-isotope SPECT WITH 201Tl and 99mTc-HMPAO. AJNR Am J Neuroradiol 12: 1187–1192, 1991

    Google Scholar 

  32. Namba H, Togawa T, Yui N, Yanagisawa M, Kinoshita F, Iwadate Y, Ohsato K, Sueyoshi K: The effect of steroid on thallium-201 uptake by malignant gliomas. Eur J Nucl Med 23: 991–992, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    V. Vallejos & M. Fraile

  2. Department of Medical Oncology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    C. Balaña & R. Rosell

  3. Department of Neurosurgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    Y. Roussos & A. Ley

  4. Department of Radiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    J. Capellades & P. Cuadras

  5. Department of Radiotherapy, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

    R. Ballester & A. Arellano

Authors
  1. V. Vallejos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Balaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Fraile
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Roussos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Capellades
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. Cuadras
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Ballester
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Ley
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Arellano
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Rosell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vallejos, V., Balaña, C., Fraile, M. et al. Use of 201Tl SPECT Imaging to Assess the Response to Therapy in Patients with High Grade Gliomas. J Neurooncol 59, 81–90 (2002). https://doi.org/10.1023/A:1016389119399

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016389119399

Search

Navigation